Research programme: pain therapeutics - Apeiron Biologics

Drug Profile

Research programme: pain therapeutics - Apeiron Biologics

Alternative Names: APN 601

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apeiron Biologics
  • Class Small molecules
  • Mechanism of Action Kv channel-interacting protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 22 Feb 2010 Preclinical development is ongoing
  • 22 Feb 2010 The programme is available for partnership (www.apeiron-biologics.com)
  • 23 Feb 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top